AstraZeneca · conference-presentation
AstraZeneca | Investor Event Presentation Deck | 52 slides
52 pages · 4 arc beats · 2 loops
AstraZeneca | Investor Event Presentation Deck | 52 slides
AstraZeneca · 2023-06 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
1246810121416182022242628303234363840424446485052
Deck intelligence map
4 coverage by narrative range · generated from this deck JSON
Narrative range 52 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Attention 7 slides 100% 7/7 slides 100% 7/7 slides · 30 hits — 0/7 slides
28.6% 2/7 slides 14.3% 1/7 slides 100% 7/7 slides — 0/7 slides
Need 7 slides 100% 7/7 slides 100% 7/7 slides · 43 hits — 0/7 slides
28.6% 2/7 slides 57.1% 4/7 slides 100% 7/7 slides 100% 7/7 slides Satisfaction 11 slides 100% 11/11 slides 100% 11/11 slides · 61 hits — 0/11 slides
36.4% 4/11 slides · 6 hits 27.3% 3/11 slides 100% 11/11 slides 100% 11/11 slides Action 27 slides 100% 27/27 slides 100% 27/27 slides · 152 hits — 0/27 slides
14.8% 4/27 slides 40.7% 11/27 slides 100% 27/27 slides — 0/27 slides
Slide inventory
52 every slide · same image gating as the playbook
04
The slide is divided into two sections: 'Speakers and panelists' and 'Therapeutic Area Leadership'.introduce_nominees
Open slide detailBeat · Attention
06
The slide uses a combination of stacked bar charts for revenue composition and a horizontal bar chart for growth metrics.analyze_data
Open slide detailBeat · Attention
07
Includes a timeline of 5 years of Plenary Presentations.summarize
Open slide detailBeat · Attention
09
The diagram illustrates a hub-and-spoke model where the central hub is 'Diverse portfolio for combinations' and the spokes are the various therapeutic areas.present_framework
10
The slide uses a timeline framework to highlight key clinical trial milestones.summarize
11
The slide features a headshot of the speaker and a medical illustration of cells.introduce_nominees
12
The slide uses a standard clinical trial process flow diagram.present_framework
13
Kaplan-Meier survival curves showing primary (2020) and updated (2023) analysis results.analyze_data
14
Includes Kaplan-Meier survival curve and 'number at risk' table.analyze_data
15
Clinical trial data visualization (Kaplan-Meier plot).analyze_data
16
The slide displays a Kaplan-Meier survival analysis with a corresponding 'number at risk' table and key statistical metrics (HR, CI, p-value).analyze_data
17
Standard forest plot used in clinical trial reporting.analyze_data
18
Includes two distinct data cut-off dates for different parts of the safety summary.analyze_data
19
Slide 20 of a presentation; includes technical definitions and study references in the footer.summarize
21
The slide uses a three-column layout to explain the product, the strategy, and the clinical trial pipeline.summarize
22
The slide outlines a clinical trial structure with six cohorts testing different combinations of Dato-DXd, pembrolizumab, and platinum-based chemotherapy.present_framework
23
Includes clinical trial abbreviations and definitions in the footer.summarize
24
The chart is a diverging stacked bar chart comparing two treatment arms. Yellow boxes highlight specific hematological toxicities.analyze_data
25
The slide uses a process flow diagram to map clinical trials to strategic goals.plan_implementation
26
Includes spider plot (target lesion change over time) and waterfall plot (best percentage change).summarize
Open slide detailBeat · Action
27
The slide uses a matrix-like layout to categorize clinical trials by disease stage and treatment line.summarize
Open slide detailBeat · Action
28
The slide uses a matrix structure to segment the market by disease stage and molecular profile, overlaying clinical trial names (e.g., AEGEAN, FLAURA) as producquantify_opportunity
Open slide detailBeat · Action
31
The slide uses a standard clinical trial flow diagram (process flow).present_framework
Open slide detailBeat · Action
32
Clinical trial data presentation showing PFS outcomes for Arm 1 (chemo + bev) vs Arm 3 (chemo + bev + durvalumab + olaparib).analyze_data
Open slide detailBeat · Action
33
Clinical trial data presentation using Kaplan-Meier plots with associated risk tables and hazard ratios.analyze_data
Open slide detailBeat · Action
34
The chart is a radial segment diagram showing patient population segments (HRD-negative, HRD-positive non-BRCAm, tBRCAm) and corresponding clinical trials.summarize
Open slide detailBeat · Action
35
The slide outlines the clinical trial methodology, specifically the randomization and treatment arms for advanced endometrial cancer.present_framework
Open slide detailBeat · Action
36
The slide features headshots of the two presenters and a scientific illustration of the drug mechanism.introduce_nominees
Open slide detailBeat · Action
37
The slide outlines a basket trial design for Enhertu across multiple solid tumor types.establish_context
Open slide detailBeat · Action
38
The table uses color-coded headers for different tumor types. The 'Best overall response' section is highlighted with a yellow border.analyze_data
Open slide detailBeat · Action
39
The slide includes a summary table at the bottom showing Median Duration of Response (DoR) for the three patient cohorts.analyze_data
Open slide detailBeat · Action
40
The chart is a classic waterfall plot used in oncology clinical trials to visualize tumor shrinkage.analyze_data
Open slide detailBeat · Action
41
The chart uses a grouped bar structure to compare IHC 3+ and IHC 2+ prevalence ranges across 8 cancer types.analyze_data
Open slide detailBeat · Action
42
Includes a headshot of the speaker and a medical illustration of blood cells/DNA.front_matter
Open slide detailBeat · Action
43
The slide illustrates the process of reweighting the ASCEND trial population to match the ALPINE trial population for a fair comparison.analyze_data
Open slide detailBeat · Action
44
The slide uses a Kaplan-Meier curve for PFS and a forest plot for safety odds ratios.compare_peers
Open slide detailBeat · Action
45
The slide is divided into two sections: Executive Leadership and Therapeutic Area Leadership.introduce_nominees
Open slide detailBeat · Action
46
The slide uses a column-based layout to map specific drug brands and pipeline assets to five major oncology therapeutic areas.summarize
Open slide detailBeat · Action
48
The slide uses a matrix-like structure to align patient segments (rows) with treatment stages (columns) and specific clinical trials (cells).plan_implementation
Open slide detailBeat · Action
49
The slide uses a matrix-like layout to map clinical trials (e.g., SERENA-4, CAPItello291) against disease stages and risk profiles.plan_implementation
Open slide detailBeat · Action
50
Kaplan-Meier survival curves showing DFS probability over time from randomisation.analyze_data
Open slide detailBeat · Action
51
The slide uses a standard clinical trial flow diagram (randomization, intervention, surgery, follow-up).present_framework
Open slide detailBeat · Action
52
The slide uses bar charts to compare clinical trial data against historical SoC benchmarks. Right chart excludes pancreatic cohort due to small sample size.analyze_data
Open slide detailBeat · Action